NASDAQ: CRVOCervomed Inc Stock
$24.99+0.39 (+1.59%)
Updated Apr 25, 2024
CRVO Price
$24.99
Fair Value Price
N/A
Market Cap
$154.20M
52 Week Low
$4.14
52 Week High
$26.38
P/E
-30.48x
P/B
20.9x
P/S
2.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.14M
Earnings
-$2.17M
Gross Margin
100%
Operating Margin
-30.4%
Profit Margin
-30.4%
Debt to Equity
0.35
Operating Cash Flow
-$7M
Beta
0.48
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CRVO Overview
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRVO is poor value based on its book value relative to its share price (20.9x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
CRVO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRVO due diligence checks available for Premium users.
Be the first to know about important CRVO news, forecast changes, insider trades & much more!
CRVO News
Valuation
CRVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-30.48x
Industry
15.41x
Market
40.97x
CRVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
20.9x
Industry
5.8x
CRVO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRVO's financial health
Profit margin
Revenue
$2.5M
Net Income
-$2.4M
Profit Margin
-94.9%
CRVO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRVO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.0M
Liabilities
$2.6M
Debt to equity
0.35
CRVO's short-term assets ($9.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRVO's short-term assets ($9.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRVO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
$0.0
Financing
-$93.4k
CRVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRVO vs Biotech Stocks
Cervomed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.